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Abstract. The retinoblastoma gene product (pRB) 
participates in the regulation of the cell division cycle 
through complex formation with numerous cellular 
regulatory proteins including the potentially oncogenic 
cyclin D1. Extending the current view of the emerging 
functional interplay between pRB and D-type cyclins, 
we now report that cyclin D1 expression is positively 
regulated by pRB. Cyclin D1 mRNA and protein is 
specifically downregulated in cells expressing SV40 
large T antigen, adenovirus E1A, and papillomavirus 
ET/E6 oncogene products and this effect requires intact 
RB-binding, CR2 domain of EtA. Exceptionally low 
expression of cyclin D1 is also seen in genetically RB- 
deficient cell lines, in which ectopically expressed 
wild-type pRB results in specific induction of this (31 
cyclin. At the functional level, antibody-mediated cy- 
clin D1 knockout experiments demonstrate hat the cy- 
clin D1 protein, normally required for (31 progression, 
is dispensable for passage through the cell cycle in cell 
lines whose pRB is inactivated through complex for- 
marion with T antigen, E1A, or E7 oncoproteins as 
well as in cells which have suffered loss-of-function 
mutations of the RB gene. The requirement for cyclin 
D1 function is not regained upon experimental e eva- 
tion of cyclin D1 expression in cells with mutant RB, 
while reintroduction of wild-type RB into RB-daficient 
cells leads to restoration of the cyclin D1 checkpoint. 
These results strongly suggest that pRB serves as a 
major target of cyclin D1 whose cell cycle regulatory 
function becomes dispensable in cells lacking func- 
tional RB. Based on available data including this 
study, we propose a model for an autoregulatory feed- 
back loop mechanism that regulates both the expres- 
sion of the cyclin D1 gene and the activity of pRB, 
thereby contributing to a G1 phase checkpoint control 
in cycling mammalian cells. 
T 
Hi~ small DNA viruses, notably the papovaviruses, 
adenoviruses, and papillomaviruses share several fea- 
tures that reflect he common eed to replicate their 
own genomes free from the restrictions which regulate DNA 
synthesis of the host cell. These viruses evolved as successful 
parasites that utilize many of the basic cellular metabolic 
processes, by intimately interacting with, and subverting the 
key points of the cell's regulatory controls (reviewed in Dy- 
son and Harlow, 1992; Fanning, 1992; Munger et al., 1992; 
Nevins, 1992). Owing to the relative simplicity of the DNA 
tumor viruses and to broad interest in mechanisms of DNA 
replication, transcription control, RNA metabolism, and 
tumorigenesis, these viruses have provided very powerful re- 
search tools and their relationship with the host cell has be- 
come a fruitful field of study. One of the unifying aspects in 
the field appears to be the°ability of the multifunctional viral 
oncoproteins: the papovavirus large T antigens, adenovirus 
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EtA proteins, and papillomavirus E7 oncogenes, to induce 
cellular DNA synthesis and thus act as potent deregulators 
of cell cycle control (Dobbelstein et al., 1992; Dyson and 
Harlow, 1992; Fanning, 1992; Munger et al., 1992). These 
three types of proteins have recently been shown to function, 
at least in part, through direct physical protein-protein inter- 
actions that arget a series of key cellular egulators includ- 
ing product of the retinoblastoma tumor suppressor gene 
(pRB), pRB-related p107, cyclin A, cyclin E, and cd1¢2 ki- 
nase (DeCaprio et al., 1988; Whyte et al., 1988; Dyson et 
al., 1989; Giordano et al., 1989; Pines and Hunter, 1990; 
Faha et al., 1993). The SV-40 large T antigen, adenovirus 
EtA, and papfllomavirus E7 proteins bind the underphos- 
phorylated, G0/Gl-specific, active form of pRB (Ludlow et 
al., 1989; Imai et al., 1991; Dyson and Harlow, 1992) thereby 
inactivating its function in a way equivalent to mutation or 
loss of the RB gene frequently seen in human neoplasias 
(reviewed in Cobrinik et al., 1992; Goodrich and Lee, 1993). 
Mutant DNA virus oncoproteins that have lost their ability 
to form complexes with pRB have significantly reduced 
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transforming potential, suggesting that binding of the RB m- 
inor suppressor by large T, E1A, and E7 oncogenes is critical 
to their oncogenic activity (reviewed in Dyson and Harlow, 
1992; Goodrich and Lee, 1993). The identification of se- 
quences within the RB protein, the so-called "RB pocket; 
responsible for its interaction with T antigen, E1A, and E7 
oncogenes stimulated the search for cellular proteins which 
would bind pRB in a manner analogous to DNA virus onco- 
proteins (Hu et al., 1990; Huang et al., 1990; Kaelin et al., 
1990). Several host proteins have recently been shown to 
specifically interact with the RB pocket domain, but the 
functions of most of those remain elusive (Huang et al., 
1991; Kaelin et al., 1991). However, there are at least two 
proteins of known functions among the RB-binding cellular 
partners and their analysis is beginning to shed some light 
on the molecular mechanisms underlying the control of cel- 
lular proliferation. One of these RB partner proteins is the 
E2F transcription factor whose target sequence is found in 
the promoters of a series of cellular genes involved in growth 
control, including several proto-oncogenes and enzymes es- 
sential for DNA replication (Bandara et al., 1991; Chellapan 
etal., 1991; Chittenden et al., 1991; Helin et al., 1992). This 
physical interaction with pRB is believed to sequester E2Fs 
transcriptional ctivity which is restored upon disruption of 
the pRB-E2F complex through cell cycle-regulated phos- 
phorylation of pRB in late G1 or via direct competition for 
the RB pocket domain by any of the above mentioned DNA 
virus oncoproteins (Bandara et al., 1991; Chellapan et al., 
1991; Chittenden et al., 1991; Helin et al., 1992). The latter 
scenario illustrates one of the molecular hallmarks haredby 
SV-40 T antigen, adenovirus E1A, and papillomavirus E7 
proteins, namely their capacity to release the transcription- 
ally active E2F from its inactive and/or transcriptionally 
repressive complex with pRB, thereby enhancing the S phase 
competence of the host cell and either promoting replication 
of the respective viral genomes (during lyric infection) or 
contributing to deregulated proliferation of the virally trans- 
formed cells (Nevins, 1992). On a similar note, the same 
RB-binding regions of these viral transforming proteins tar- 
get the RB-related p107 host protein whose complexes with 
either E2F alone or E2F, cyclin A and cdk-2 are present dur- 
ing (31 and whose multiprotein interactions involving E2F 
together with cyclin A and edk2 kinase are believed to per- 
form a regulatory role during S phase (Bandara et al., 1991; 
Ewen et al., 1991; Mudryj et al., 1991; Lees et al., 1992; 
Pagano et al., 1992a; Shirodkar et al., 1992). The Gl-spe- 
cific pl07-E2F complex has recently been implicated in reg- 
ulation of the E2F's transcriptional ctivity at the {31 > S tran- 
sition (Schwarz et al., 1993) and it remains to be seen if the 
respective functions of RB-E2F- and pl07-E2F-containing 
complexes in G1 phase progression are unique or redundant. 
The most recent addition to the list of cellular RB-binding 
proteins appear to be the D-type cyclins (Lew et al., 1991; 
Matsushime t al., 1991; Motokura et al., 1991; Xiong et 
al., 1991). Cyclin D1, D2, and D3 have been shown to inter- 
act with unphosphorylated an /or underphosphorylated pRB
via their NH2-terminal L-X-C-X-E motifs analogous to 
those present in homology regions II of the DNA virus on- 
coproteins (Dowdy et al., 1993; Ewen et al., 1993; Kato et 
al., 1993). Complexes of D-cyclins with the cdk4 kinase 
efficiently phosphorylate pRB in vitro and in insect cells, but 
unlike other cyclin-cdk complexes, they are inefficient in 
phosphorylating histone H1 (Kato et al., 1993; Matsushime 
et al., 1992; Xiong et al., 1992). This substrate selectivity 
may indicate that cyclin D-cdk4 is a relevant pRB kinase in 
vivo and that the physical interaction of D-cyclins with pRB 
may therefore help to direct cdk4 to this substrate during (31 
phase, resulting in pRB phosphorylafion a d the inactivation 
of pRB's growth-constraining function. Although provoca- 
five, the experimental evidence for functional interaction of 
pRB and D-type cyclins is largely based on experiments per- 
formed in vitro and its relevance to regulation of G1 progres- 
sion and/or (31 > S transition in a living cell remains to be 
rigorously established. 
Given that the important cell cycle control points are fre- 
quently targeted by the transforming DNA virus oncopro- 
teins and intrigued by our preliminary observation of strik- 
ingly low cyclin DI protein levels in several human cell lines 
either transformed by DNA virus oncogenes or harboring 
RB gene mutations (Bartek et al., 1993a; Lukas et al., 1994), 
we decided to investigate the potential functional relation- 
ship between these viral transforming proteins, pRB and cy- 
clin D1, in more detail. We now report hat pRB plays a posi- 
tive role in regulation of cyclin D1 expression and that SV-40 
large T antigen, adenovirus EIA, papillomavirus ET/E6 pro- 
teins, and inactivating RB gene mutations share the capacity 
to eliminate the requirement for functional cyclin D1 in regu- 
lation of (31 phase progression. 
Materials and Methods 
Cell Culture and Synchronization 
HumAn diploid fibroblasts (IMR-90 and MRC-5) were purchased from the 
American Type Culture Collection. The UMSCC-2 squamous carcinoma 
cell line was provided by T. Carey (University of Michitmn, Ann Arbor, 
MI), the rat RetA7 cells conditionally transformed by the A7 ts mutant of 
the SV40 large T antigen gene were obtained from M. Graessmann (Free 
University, Berlin, C~'many); the human skin kemtinocyte-d~ved c ll line 
HaCaT was donated by N. E. Fuseul 8 (German Cancer P, esearch Center, 
Heidelberg, Germany); bunch embryonic retina cells (HER) ~ by (X Kranen- 
burg (Sylvius Laboratory, Leiden); and the SW756 cell line, originally de- 
rived from a squamous cell carcinoma nd shown to display hormone- 
dependent cmpression f IiPV 18 E7/E6 as a result of integration of the HPV 
genome in the vicinity of a dera~,~ne-responsive cellular sequence 
(yon Knebel Doeberitz et al., 1991), was a gift of M. yon Knebel Doeberitz, 
German Cancer Research Center, Heidelberg, Germany. Primary mam- 
mary epithelium (RME), primary human foreskin fibroblasts (HFF), and 
the human tumor-derived cell lines were obtained from the collections of 
the Department of Cell Cycle and Cancer (Danish Cancer Society, Copen- 
hagen, Denmark) and the ATV Collection (German Cancer Research Cen- 
ter), and their names and origins are listed in Tables I and lI. The cells were 
cultured in DME supplemented with 10% FCS, 2 mM glutamine, 10 U/ml 
penicillin, and I0 U/ml ~ .  The RMT-1 and RMT-2 lines were s- 
tablished in the present study, using the retmviral vector-mediated gene 
transfer to immortalize the normal human mammary epithelial (RME) cells 
via expression of the SV-40 large T antigen. The amphotropic retroviral vec- 
tor and the infection and selection procedures used in this study were essen- 
tially as described by Bartek et al. (199D. 
Tumor cell lines were synchronized inmitosis by 18 h incubation in the 
presence of 40 ng/ml nocodezole (Sigma , St. Louis, MO). The rounded 
cells were subsequently detached from the substrate by gentle shakin 8 and 
pipettin8 up and down. After two washes in fresh DME without nocodazole 
the cells were replated into fresh medium and two hours later, the nonat- 
tached cells were washed out. Progression through the cell cycle was moni- 
tored by flow cytometry (FACScan; a registered trademark of Becton Dick- 
inson Immunocytometry S s., Mountain View, CA) aft~ staining DNA 
with 50 ttg/ml propidium iodide (Sit, ma) in the presence of 10 ~g/ml 
1. Abbreviations uaed in this paper: BrdU, bromodeoxyuridine; CRBP, cel- 
lular Rb-binding proteins; HER, human embryonic retina cells; HFF, pri- 
mary human foreskin fibroblasts; RME, primary maEflmary epithelium. 
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DNAse-free RNAse (Boehringer Mannheim GmbH, Mannbeim, Ger- 
many). Alternatively, bromodeoxyuridine (BrdU; SiTn~) or [6-3H]thymi - 
dine (Amersbam Corp., Arlington Heights, IL) incorporation was moni- 
tored (see micminjection paragraph for details). 
Antibodies 
The DCS-6 mouse monoclonal ntibody (1gG2a) specific for cyclin D1 pro- 
tein, appficable in immunoblotting, immunocytochemistry, and immuno- 
precipitation, has recently been described by Lukas et al. (1994). The rabbit 
polyclonal antisera a~inst human cyclin D1 (Baldin et al., 1993) and human 
cyclin A (Pagano et al., 1992b) were obtained from M. Pageno and G. 
Draetta (Mitotix, Cambridge, MA), rabbit anti-cdk4 and anti--cdk6 an- 
tisera were a kind gift from G. Peters (ICRF, London, UIO. Mouse mono- 
clonal antibodies to human cyclin A (Giordano et al., 1989), adenovirus 
EIA (Harlow et al., 1985), human p107 protein and cyclin E (Lees et al., 
1992) were provided by E. Harlow, Kristian Helin, and E. Lees (MGH Can- 
cer Center, Charlestown, MA) and the mouse mAb PAb419 to SV-40 T anti- 
gen was obtained from D. Lane (CRC Laboratories, Dundee, Scotland). 
Anti-BrdU monoclonal antibody was purchased from (Partec Reinach, 
Switzerland) and diluted 1:50, FI1~-conjugeted rabbit anti-mouse IgG an- 
tibody was obtained from Si~mm and diluted 1:100. Biofinylated antiserum 
to mouse immunoglobulin a d Texas red--conjugated streptavidin were from 
Vector Laboratories (Burlingame, CA). 
Immunocytochemistry 
Cell monolayers growing on glass coverslips were rinsed in PBS and fixed 
for 10 min in cold methanol-acetone (1:1) or for 5 min in 100% methanol 
followed by a 2-rain treatment in acetone at -20°C. Fixed cells were re- 
hydrated in PISS at room temperature and processed for cell staining. 
Anti-cyclin D1 ascitic fluid was diluted 1:200, hybridoma supernatants were 
used nondfiuted. Incubation with primary antibodies was carried out over- 
night at 4"C in a humidified cbamber. After three washes in PBS the cover- 
sliln were incubated for 1 h at room temperature with biotinylmed horse 
anti-mouse condary antibody (dilution 1:150; Vector Laboratories). Cells 
were washed amtin three times with PBS and incubated with Texas red-con- 
jugated streptavidin (dilution 1:100; Vector Laboratories). After a final 
wash with PBS, immunofluorescence samples were directly mounted in 
GelvatoL Counterstalnln~ for DNA was performed by adding 1 #g/ml bis- 
b~nzimide (Hoechst 33258; Sigma) into the final PBS wash. The cells in 
S-phase were detected by thymidine incorporation followed by in situ auto- 
radiography as described by Lukas et al. (1994). 
Gel Electrophoresis and lmmunoblotting 
Total cell extracts were prepared by in situ direct lysls of cell monolnye~ 
with hot Laemmli sample buffer (without bmmophenol blue). Protein con- 
centration was measured using the Bio-Rad SDS-compatible DC Protein 
Assay kit. Extracted proteins were electmphor~c~lly selmrated on 12.5% 
SDS-PAGE. Gels were either stained with Coonmssie blue to control for 
the bslanced loading or blotted onto nitrocellulose (Schleicher and Schuell 
Inc., Keeue, NH) by semi-dry method (Lukas et al., 1994). Filters were 
subjected to immunoblotting using the ECL (Amersham Corp.) detection 
system according to the mamifilcturer's imtrucfions. 
Northern Blot Analysis 
Total cellular RNA was extracted by the 8uanidlnium thiueyanateJa~d phe- 
nol method. 10 ~g of RNA was electrophoresed on 1% agarose formalde- 
hyde gels and tramferred onto nylon membranes. Expression of cyclin D1 
was monitored with either the mouse cyl 1 probe (Matsushime etal., 1991) 
or the human probe (Xiong et al., 1991), dependent on whether rodent or 
primate cells were analyzed. Glyceraldchyde-3-phosphate dehydrogemse 
mRNA expression was analyzed in parallel to control for balanced gel 
loading, 
Micminjection and Electropomtion 
Cells were synchronized by nocodazole shake-off as described above and 
microinjected upon replating and attachment, using the automatic microin- 
jecfion system (AIS; Carl Zeiss, Inc., Thomwood, NY) as described previ- 
ously (Bald/n et el., 1993). Affinity-purified anti-cyclin DI monoclonal nd 
polyclonal antibodies, or control rabbit or mouse preimmmle immunoglob- 
ulin (2 mg/ml in PBS) were microinjected into the cympIHm or directly 
into the cell nucleus. Immediately after microinjection, the growth medium 
was mpplemented with BrdU at a final concentration f 100 ~M or trifiated 
thymidine at 1 ¢Ci/ml. Cells were incubated until they reached the peak 
of S-phase (80% or more BrdU/thymidine-positive cells; the time vm'ied be- 
tween 18 and 32 h after eplating, depending on the cell line) and fixed and 
stained for BrdU or developed for autoradiography (see above). Alterna- 
tively, the nocod~ole-synchronized cells were elect~porated by the 
purified antibodies following the protocol developed by Lukas et al. (1994). 
The effect of elect~porated antibody on the progression of cells into 
S-phase was analyzed by means of combined immunofluoreseence (toiden- 
tify the immtmoglobulin-containin~ cells)al~ [6-3H]thymidinc incorpora- 
tion/autoradiography at selected time points as indicated in the text. For 
each time point, 200 immtmoglobulin-containin~ cells per coverslip were 
scored for evidence of thyroid/no incorporation. The data are expressed as 
the mean value of percentage of S-phase inhibition, obtained by comparison 
of the fractiom of S-phase cells in the controls (treated with normal mouse 
or rabbit Ig, which had no detectable effect on S-phase ntry) with S-phase 
cells in the anti--cyclin D1 antibody-treated c ll populations, respectively. 
This value is close to zero in cells refractory to cyclin D1 knockout while 
it commonly reaches 50-60% in cells with the preserved cyclin DI function 
in (31. Each eloctroporefion and/or microinjection result was verified by 
three independently performed experiments and the data statistically evalu- 
ated by estimating standard deviations. Essentially identical electmporation 
protocol ( I . J~  et al., 1994) was employed for the gene transfer experi- 
ments using the pSV-ueo (a gift f~m C. Norbury, ICRF, Oxford, UK), 
pCMV-DI (Baldin et al., 1993), pCMV and pCMV-RB (M~ller et al., 
1994), pCMV-ueo, pCMV-EIA-Ueo, and pCMV-E1A ACR2-neo (Fattaey 
et al., 1993), either individually or as a combination of pCMV-RB or 
pCMV-D1 with pSV-neo at a 10:1 ratio. 
Results 
Cyclln D1 Is Downregulated bySeveral Oncogenes 
Encoded by the Small DNA Tumor Viruses 
Stimulated mainly by the accumulating evidence for the on- 
cogenic potential of cyclin D1, its mRNA levels in human cell 
lines of various tissue and tumor origin have been inves- 
tigated by several groups and found to be higldy variable 
(reviewed by Motokura and Arnold, 1993). Our recent im- 
munoblotting analysis of cyclin D1 abundance in a large 
panel of human cell lines revealed low levels of the cyclin D1 
protein in several lines transformed by small DNA tumor 
viruses (Bartek et al., 1993a; Lukas et al., 1994). To inves- 
tigate this intriguing correlation in a more systematic way, we 
have now collected a considerably wider range of cell lines 
immortalized and/or transformed by SV-40 T antigen, 
adenovirus E1A, or papillomavirus E7/E6 oncogenes (see 
Table I), prepared and electrophoretically separated the 
whole cell lysates from exponentially growing cultures of all 
the cell types listed in Table I and probed the corresponding 
blots with both our new mouse monoclonal antibody DCS-6 
specific for cyclin D1 (Lukas et al., 1994) and a well charac- 
terized rabbit anti-cyclin D1 antiserum (Baldin et al., 1993). 
The immunoblotting analysis revealed only moderate varia- 
tion of cyclin D1 abundance among the control cell lysates 
(see Fig. 1, lanes 1, 3, and 5, for examples). In contrast, we 
found signifcandy reduced cyclin D1 levels in all the DNA 
virus oncogene-expressing cell lines as compared to several 
control cell types (Fig. 1 and Table I). Quantitative valua- 
tion of the ECL blots by laser densitometry showed this 
reduction to be in the range of nine times or more, depending 
on a cell line. The control counterpart cell types included 
several nonestablished cell strains and/or primary cultures 
(MRC5, IMIL00, HFF, and RME), monkey CV-1, mouse 3T3 
cells, and a series of human cancer cell lines, some of which 
have repeatedly been reported to contain a single copy cyclin 
D1 gene (Table I). The overall correlation of the low cyclin 
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Table L Downregulation of Cyclin D1 in Cells Expressing DNA Virus Oncogenes 
Cell line Origin* Viral oncoprotein D1 protein~ DlmRNA~ 
IMR90 Diploid fibroblast - + + + ND 
MRC5 Diploid fibroblast - + + + ND 
HFF Primary fibroblast - + + + ND 
3T3 Established fibroblast - + + + ND 
RME Breast Epithelium - + + + ND 
CV-1 Kidney epithelium - + + + + + + 
MCF-7 Breast carcinoma - + + + + + + 
T47D Breast carcinoma - + + + + + + 
SK-LMS-1 Leiomyosarcoma - + + + ND 
UMSCC-2 Squamous cell ca. -- + + + ND 
I-IaCaT Keratinocytes - + + + + + + 
Cos7 Derivative of CVl SV40 T Ag + -4- 
HBL100 Breast epithelium SV40 TAg + + 
RMT-1 Derivative of RME SV40 T Ag + ND 
RMT-2 Derivative of RME Sv40 T Ag + ND 
Ref A7/32°C Fibroblast/permissive SV40 TAg(+) + ND 
Ref A7/39°C Fibroblast/nonpermissive SV40 T Ag(-)  + + + ND 
293 Transformed fibroblast E1A,E1B + + 
IREE-1 Fibroblast/cestrogen ( - )  E1A(-) + + + + + + 
IREE-1/E FibroblastJcestrogen (+) E1A(+) + + 
M107-Ad5 Infected fibroblast E1A(+),E1B(+) + + 
M107-d1312 Infected fibroblast EIA(-),E1B(+) + + + + + + 
HeLa Cervical carcinoma HPVI8 E7/E6 + + 
C4-1 Cervical carcinoma HPV18 E7/E6 + ND 
444 HeLa/flbroblast hybrid HPVI8 E7/E6 -I- ND 
Cgl3 HeLa/flbroblast hybrid HPVI8 E7/E6 + ND 
SW 756 Cervical carcinoma HPV18 (E7/E6)(+) + ND 
SW756/Dex Cervical carcinoma HPVI 8 (E7/E6)(-) + + + ND 
SiHa Cervical carcinoma HPVI6 E7/E6 + ± 
HPK 1A Immortal keratinocyte HPV16 E7/E6 + ± 
CaSki Cervical carcinoma HPV16 E7/E6 ± ± 
* All cell types are of human origin, except for CV-1/Cos-7 (green monkey), RefA7 and IREE-1 (both rat),and 3T3 (muse). 
The immunoblotting and/or Northern blotting data were compared bydensitometric scanning and the cyclin D1 expression estimated according toan arbitrary 
scale, graded as + + +, ,and+. 
ND, not determined. 
Figure 1. Expression of cyclin DI protein and mRNA is abnormally 
low in cell lines transformed by small DNA tumor viruses. (A) Cy- 
clin DI protein abundance is reduced in cells constitutively express- 
ing the SV40 T antigen (COS-7,/-/BL/00, RMT-1), I-IPV18 E7/E6 
(HeLa) and adenovirns 5 E1A/E1B (293) oncogenes. The control 
cell lysates from CV-1, MCF7, and RME show the standard levels 
of ~yelin I)1 protein in nsynchronously growing cells lacking DNA 
viral oncogenes. The immunoblotting reactions are visualized by 
the ECL method and the molecular mass of the markers is given 
in kD. (B) Northern blot analysis of cyclin D1 mRNA expression. 
Gel separated RNA, isolated from HaCaT (lane 1), Cos-7 (lane 2), 
and CV-1 (lane .3) cells, was blotted and probed with the cyclin D1 
cDNA probe to reveal the substantial reduction of both cyclin D1 
transcripts in the SV-40-transformed Cos-7 cells. 
D1 levels with the presence of a DNA tumor virus oncogene 
was further strengthened by the fact that included in our 
panel was also a closely matched pair of SV40 T anti- 
gen-transformed cell lines and their parental line lacking the 
viral oncogene (CosT versus C~1 cells) (see Fig. 1 and Table 
I). In addition, two new cell ines (designated RMT-1 and 
RMT-2) were established as part of this project from the 
RME normal mammary epithelium via retroviral-mediated 
introduction of the SV-40 T antigen. Cyclin D1 expression 
was found to be dramatically reduced in both RMT-1 and 
RMT-2 as compared to the parental RME cells (Fig. 1 and 
Table I), and repeated examination of these, and a few other 
cell lines included in Table I, over the period of more than 
12 mo revealed that the expression level of cyclin D1 protein 
appears to be a relatively stable feature of each cell type 
(data not shown). To demonstrate he downregulation f cy- 
clin D1 expression by the viral oncoproteins even more 
directly, we also employed two cellular model systems in 
which expression of either the papillomavirus ET/E6 pro- 
teins or the SV-40 T antigen can be manipulated by culture 
conditions. First, as can be seen from Fig. 2 A, release from 
the dexamethasone-mediated suppression ofthe E7/E6 onco- 
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Figure 2. Regulation of cyclin 
D1 protein levels by condi- 
tionally expressed DNA tu- 
mor virus oncogenes. (A) 
Upregtdated expression of 
HP3/18 E7/E6 oncogenes 
leads to decreased accumula- 
tion of the cyclin D1 protein. 
SW756 cell line contain- 
ing dexamethasone-repres- 
sible I-1PV18 E7/E6 was grown 
without the presence of dexa- 
methasone and the selected 
time-points were sub~lnently 
analyzed for the cyclin D1 pro- 
tein levels. (B)Cyclln DI pro- 
tein is selectively downregu- 
lated by HPVI8 E7/E6 since 
the levels of cyclins A and 
E remain approximately con- 
stant upon E7/E6 induction. 
SW756 cell line was grown 
with (positive lanes) and with- 
out (negative lanes) dexamethasone as described in Materials and 
Methods and the levels of eyclins D1, A, and E were analyzed by 
ECL immunoblotting. (C) Regulatable expression of SV-40 T anti- 
gen selectively influences eyclin DI protein expression. Rat Ref 
cells (clone A7) expressing the A7 temperature-sensitive mutant of 
SV40 large T (see Materials and Methods) were grown at pe mis-
sive temperature (32"C) or at nonpermissive temporamre (48 h at 
39°C) and the protein levels of yelin D1 and eyclin A were ana- 
lyzed by immunoblotting. 
gene expression in the SW756 cells resulted in time- 
dependent s epwise decrease of the cyclin D1 protein abun- 
dance. The cyclin downregulation by E7/E6 appears to be 
specific for cyclin D1 since parallel immunoblots probed 
with antibodies to cyclin E and A revealed no significant 
variation dependent on expression of these viral oncogenes 
(Fig. 2 B). Second, the rat embryo fibroblast cells condition- 
ally transformed bythe A7 temperature-sensitive mutant of 
SV-40 T antigen expressed significantly less cyclin D1 pro- 
tein when grown at 32°C (i.e., the temperature permissive 
for large T antigen function in these cell~) as compared with 
the cyclin levels at the nonpermissive t mperature (Fig. 2 
C). Since the expression of both cyclin E and A is tightly 
regulated uring the cell cycle, the observed lack ofany ap- 
preciable differences in abundance of these two cyclin pro- 
teins in virus oncogene-containing cells argues against any 
viral oncogene-induced gross shift in the relative propor- 
tions of cells in various cell cycle phases. Furthermore, to 
exclude the theoretical possibility that the low level of cyclin 
D1 in the presence of viral oncoproteins i due to dramati- 
cally reduced fraction of cells in the G1 phase, i.e., the 
period of the cell cycle when cyclin D1 is expressed at the 
highest level (Motokura et al., 1992; Baldin et al., 1993; 
Musgrove t al., 1993; Bartkova et al., 1994; Lukas et al., 
1994), we explored two additional approaches. First, the 
FACSCan analysis of DNA profiles of exponentially growing 
cell populations howed only minor differences in propor- 
tions of (31 cells, the extent of which cannot account for the 
pronounced ownregulation of cyclin D1 seen in cell lines 
expressing the DNA virus oncogenes (data not shown). The 
second approach was based on our earlier immunostaining 
data obtained with synchronized normal and tumor cell 
populations, which demonstrated that cyclin D1 was clearly 
detectable inG1 nuclei but low or absent in the other cell cy- 
cle phases (Baldin et al., 1993; Bartkova et al., 1994; Lukas 
et al., 1994; see Fig. 3, A, B, and Cfor example), If the ob- 
served low levels of cyclin D1 protein in the viral oncogene- 
expressing cells were simply due to shortening of the 131 
phase, one would predict hat there would still remain a de- 
tectable albeit smaller proportion of brightly stained, cyclin 
Dl-positive, (31 cell nuclei. The immunoituorescence exami- 
nation of the viral oncogene-expressing cell lines HeLa, 293, 
HBL-100, RMT-1, RMT-2, and Cos-'/consistently showed 
an overall ow:staining signal, which is consistent with the 
general inhibition of the cyclin D1 expression rather than 
selective shortening of the G1 phase (data not shown). 
From the data described above we conclude that the SV-40 
large T antigen, papillomavirus E7/E6, and adenovirus E1A 
oncoproteins selectively downregulate he expression of cy- 
clin D1 protein in the host cell. The Northern blot analysis 
with cyclin D1 gene probe of RNAs isolated from several cell 
lines included in our panel (see Table I) revealed very low 
abundance of both cyclin D1 gene transcripts in cells ex- 
pressing the viral oncogenes, when compared with the con- 
trol group of cell types (Fig. 1 B and Table I). This result 
indicates that the observed effect of the viral oncoproteins on 
cyclin D1 expression is primarily caused by a mechanism 
operating at the mRNA level (inhibition of transcription 
and/or lower RNA stability) and that the low abundance of 
the cyclin D1 protein is likely to reflect he level of available 
transcripts rather than abnormaLities at the level of transla- 
tion or cyclin D1 protein degradation. 
NA Virus Oncoproteins Eliminate the Host Cell's 
uirement for Functional Cyclin 1)1 
The experimental knockout of cyclin D1 achieved by micmin- 
jection of either affinity-purified rabbit antibodies to cyclin D1 
or antisense plasmids into synchronized human diploid fibro- 
blasts in early 131 prevented entry into S-phase (Baldin et al., 
1993). Microinjection performed in late G1, however, had no 
effect on subsequent onset of DNA synthesis, leading to the 
conclusion that cyclin D1 function is required for (31 pro- 
gression (Baldin et al., 1993). Using an analogous strategy, 
we have recently developed an improved functional knockout 
approach for cyclin D1 based on electroporation f affinity- 
purified high titre mouse monoclonal antibody DCS-6 and 
employed this technique to demonstrate hat cyclin D1 is re- 
quired for progression through (31 in several human tumor- 
derived cell types including the MCF-7 and UMSCC-2 car- 
cinoma lines (Luhs et al., 1994). In this study, we examined 
whether the observed ownregulation of cyclin D1 by DNA 
tumor virus oncogenes is accompanied by any functional 
effect and asked whether the remaining low levels of the cy- 
clin D1 protein continue to play an essential role in the cell 
cycle progression. To assess the requirement for functional 
cyclin D1 in various cell types, we electroporated the affinity- 
purified DCS-6 antibody into mitotic cells, allowed the cells 
to proceed into the cell cycle, and added tritiated thymidine 
to monitor DNA synthesis, followed by fixation at specified 
time intervals and processing for immunofluorescence and
autoradiography. The proportion of successfully electropo- 
rated cells, as indicated by the presence of mouse immuno- 
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Figure 3. Analysis of cyclin D1 sub- 
cellular localiz~on, cell cycle-telzted 
variation, and effect of the antibody- 
mediated cyclin D1 knockout in 
MCF'/ cell line. (A-C) Combined 
immunofluorescence and autoradi- 
ography analysis demonstrating stan- 
dard levels, nuclear targetting of the 
cyclin D1 protein and its low abun- 
dance in S-ptme ce~. (L~-F) ana (C,-- 
1) show examples ofelectroporation 
into MCF-7 ceils of DCS-6 mono- 
clonal antibody and of control mouse 
IgG, respectively. While the cells 
treated with DCS-6 are prevented 
from entering S phase (D-F), the 
control ceils synthesize their DNA 
irrespective of the antibody treat- 
ment (G-/). (A) shows immunostain- 
ing with anti-D1 monospecific mono- 
clonal antibody DCS-6; (D and G) 
show positively electroporated cells 
revealed by anti-immunoglobulin 
staining; (B, E, and H) demonstrate 
thymidine incorporation monitored 
by,,in situ autoradiography; (C, F,
and I) reveals nuclei counterstained 
by Hoechst. The arrowheads point to 
the same nuclei in corresponding trip- 
lets of microplmtographs. Bar, 10/an. 
globulin visualized by immunofluorescence in the adherent 
cell population was reproducibly within the range of 40-80%. 
Microphotographs in Fig. 3 illustrate the results of a typical 
electroporation experiment in control MCF-7 cells. Ceils 
electroporated with the anti-cyclin D1 mAb were prevented 
from entering the S-phase (Fig. 3, D-F) while control anti- 
bodies showed no significant inhibition (Fig. 3, G-I). In a 
control experiment, introduction of the same DCS-6 anti- 
body preparation i to late G1 cells was no longer effective. 
This result suggested that the cells passed the cyclin D1- 
dependent checkpoint by late (31 and, at the same time, ex- 
cluded the possibility hat he S-phase inhibition was caused 
by some toxic component in the electroporation solutions 
rather than the specific effect of the antibody. Overall, five 
different cell types from the control series lacking any DNA 
tumor virus oncoprotein were examined: normal human 
diploid fibroblasts (IMR90), established but nontransformed 
CV-1 cells, the cell lines derived from a breast carcinoma 
(MCF-7), leiomyosarcoma (SK-LMS-1), and the UMSCC-2 
squamous ceil carcinoma. In every case, electroporation f 
the anti-cyciln D1 mAb caused a severe delay of DNA syn- 
thesis (see Fig. 4 for examples). In contrast to cell cycle inhi- 
bition observed for the control normal cells and cell lines de- 
rived from tumors of nonviral pathogenesis, electroporation 
for the DCS-6 antibody into synchronized cell lines express- 
ing SV40 T antigen (HBL-100, Cos-7), adenovirus E1A (293 
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Figure 4. Effects of the anti-cyclin D1antibody (DCS-6) electropo- 
ration into various cell types upon S-phase entry. The cell lines not 
transformed byDNA virus oncogenes are significantly delayed in 
their onset ofDNA synthesis as shown for 3T3 (/), CV-1 (2), and 
MCF-7 cells (3), while no obvious effect is seen in case of vitally 
transformed Cos-'/(4), HBL100 (5) HeLa (6), and 293 (7) cell 
lines. Each experiment was performed three times, the data are ex- 
pressed as graphs summarizing the mean percentage of S-phase in- 
hibition by DCS-6 and the extent of an experimental error is indi- 
cated by standard deviation bars. 
cells), and papilloma E6/E7 (HeLa cells), had no detectable 
effect upon entry into S-phase (Fig. 4). 
Two additional sets of experiments were subsequently per- 
formed to investigate the specificity of this phenomenon. 
The first set of control experiments confirmed the require- 
ment in control cell types and the lack of dependency on cy- 
clin D1 for G1 progression i the HBL-100, HeLa, and 293 
viral oncogene-transformed cell lines using a different set of 
reagents: the affmity-puritied rabbit anti-cyclin D1 poly- 
clonal antibodies and normal rabbit immunoglobulin, for 
electroporation (data not shown). In addition, the S-phase 
entry was delayed to a similar extent also upon microinjec- 
tion, rather than electroporation, of the DCS-6 monoclonal 
antibody into early (31 cells (an approach control, data not 
shown). 
In conclusion, these data demonstrate a common loss of 
dependency on the function of cyclin D1 in cell lines trans- 
formed by the SV-40 large T antigen, adenovirus E1A, and 
papillomavirus E7/E6 oncoproteins. 
Retinoblastoma Protein Is Involved in Regulation of  
Cyclin D1 Expression 
One hallmark shared by T antigen, E1A, and E7 is their ca- 
pacity to form complexes with the retinoblastoma protein, 
thereby preventing its interaction with cellular partner pro- 
teins and resulting in functional inactivation of pRB 
(DeCaprio et al., 1988; Whyte et al., 1988; Dyson et al., 
1989). We reasoned that one way to address the question of 
whether or not the above effects of various oncoproteins on 
cyclin D1 could be mediated by inactivation of pRB, is to ex- 
amine the expression and properties of cyclin D1 in cancer 
cell lines harboring naturally occurring mutations of the RB 
gene. We therefore performed a comparative immunoblot- 
ring and immunofluorescence study of cyclin D1 in a panel 
of RB-defective cell lines and histogenetically matched con- 
Figure 5. Immunoblotting 
analysis ofpRB, cyclin A, and 
cyclin D1 abundance in hu- 
man cancer cell lines. Equal 
amounts 0£ total cellular lysates 
~ from MCT-7 (lane 1), 
BT-549 0ane 2), MDA-468 
(lane 3), Hs913T (lane 4) ,  
DU4475 (lane 5), SKLMS-1 
(lane 6), Saos-2 (lane 7), and 
C33-A (lane 8) cells were separated by SDS-PAGE, the cor- 
responding blots probed with the antibodies as indicated on the 
fight, and the reaction visualized by the ECL method. Although not 
visible on this exposure, the low levels of cyclin D1 in BT-549 and 
Saos-2 cells, as well as the truncated i05 RB in Saos-2 extract were 
detectable upon longer exposures. 
trol cell types containing normal RB gene and functional RB 
protein. Of the ten rumor cell lines with RB mutations avail- 
able for this study, six suffered gross aberrations resulting in 
a total loss of the RB protein, while four lines carry more 
subtle RB gene deletions and the corresponding abnormal 
RB polypeptide is expressed in these cells albeit at lower 
level (see Table II for details and Fig. 5, top for pRB detec- 
tion on immunoblots). The control series of cell types with 
normal RB gene included breast carcinoma, lung carcinoma, 
and sarcoma lines, as well as normal human retina cells, thus 
matching most of the RB-defective lines as to their origin 
Ohble 11). Apart from their histogenesis and reported lack 
of RB gene abnormalities, the criteria for selecting these 
control cell lines were: (a) spontaneous es tab~ent  in 
vitro without any involvement of the DNA tumor viruses; 
and (b) the expression of functional RB protein as judged 
from its nuclear localization, apparent molecular mass as 
predicted for wild-type pRB, phosphorylation status and the 
capacity to form complexes with SV-40 T antigen upon infec- 
tion of these cancer cell lines with SV-40 virus (Lee et al., 
1988; TAng et al., 1988; Horowitz et al., 1990; Shew et al., 
1990; Stratton et al., 1990; Bartek et al., 1992). Further- 
more, presence of well defined p53 gene mutations i  ome, 
and of the wild-type p53 in other cell lines of this control cat- 
egory (Casey et al., 1991; Bartek et al., 1993b) should facili- 
tate detection of any obvious effects of p53 aberrations on cy- 
clin D1 expression i  cells expressing normal RB. 
To compare cyclin D1 protein abundance in the control and 
the RB-defective lines, blots of SDS-PAGE-separated whole- 
cell lysates from exponentially growing cultures of the cell 
lines listed in Table 1I were probed with our monoclonal nti- 
body DCS-6 (Lukas et al., 1994) and the rabbit antiserum 
(Baldin et al., 1993) against human cyclin D1. One blot was 
cut in half and the upper and lower parts of the membrane 
were probed with anti-cyclin A and anti-cyclin D1 antibod- 
ies, respectively. As can be seen from an example shown in 
Fig. 5 and from the summary of the immunoblotting data in 
Table II, all the control cell types expressed easily detectable 
cyclin D1 protein levels, comparable to those found in cul- 
tured normal diploid cells, while strikingly reduced abun- 
dance of this cyclin was observed in the cancer cell lines har- 
boring mutant RB. Although not visible on the exposure 
shown in Fig. 5, low levels of cyclin D1 protein could be de- 
tected even in the cell lysates from Saos-2 and BT-549 cells 
upon longer exposure of the ECL blots. The cyclin repres- 
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Table II. Cyclin 1)1 Protein Levels in Cell Lines with Normal and Mutant RB 
Cell line Origin RB gene* RB protein* Cyclin DI* 
BT549 Breast cancer Gross rearrangement None + 
MDA-468 Breast cancer Gross rearrangement None + 
DU4475 Breast cancer Gross rearrangement None + 
Hs913T Fibrosarcoma Gross rearrangement None + 
WERI-1 Retinoblastoma Gross rearrangement None + 
Y-79 Retinoblastoma Deletion of exons 2-6 None ± 
Saos-2 Osteosarcoma Deletion of exons 21-27 p95 ± 
NCI-H69 Small cell lung cancer Deletion of exon 22 pl00 + 
NCI-592 Small cell lung cancer Deletion of exon 22 pl00 ± 
C33-A Cervical cancer Partial deletion in exon 20 p104 ± 
PMC-42 Breast cancer Normal Normal + + + 
MCF-7 Breast cancer Normal Normal + + + 
ZR-75 Breast cancer Normal Normal + + + 
MDA-231 Breast cancer Normal Normal + + + 
BT474 Breast cancer Normal Normal + + + 
CamA 1 Breast cancer Normal Normal + + + 
MDA-157 Breast cancer Normal Normal + + + 
SK-BR-3 Breast cancer Normal Normal + + + 
HER Normal retina cels Normal Normal + + + 
U-2-OS Osteosarcoma Normal Normal + + + 
RD Rhabdomyosarcoma Normal Normal + + + 
SK-LMS-1 Leiomyosarcoma Normal Normal + + + 
Calu Lung carcinoma Normal Normal + + + 
HT 29 Colon cancer Normal Normal + + 
DLD-1 Colon cancer Normal Normal + + + 
* The data on RB gene and protein are from: Lee et al., 1988a,b; T-Ang et al., 1988; Horowitz et al., 1990; Shew et al., 1990; Stratton et al., 1990; Scheffner 
et al., 1991; Bartek et al., 1992. 
The immunoblotting data were compared by densitometric scanning and the cyclin D1 protein level estimated according to an arbitrary scale, graded as + + +, 
++, +, and ±. 
sion shared by the RB-defective lines appeared to be specific 
for cyclin D1 since no obvious differences in cyclin A expres- 
sion could be found when cell lines carrying normal or mu- 
tant RB genes were compared (see Fig. 5 for examples). The 
latter esult also impfies that all the cell lines examined were 
proliferating at the time of analysis, the conclusion which 
was independently confirmed by FACScan analysis of DNA 
profiles and thymidine incorporation i several cell lines of 
either category (data not shown). The immunofluorescence 
analysis of cyclin Dl-expression patterns confirmed and ex- 
tended the above immunoblotting data. Thus, while the ex- 
ponentially growing cell lines expressing normal  RB showed 
the characteristic nuclear staining of highly variable inten- 
sity (see Fig. 3 A for example), very weak to undetectable 
cyclin D1 staining signal was found in all ten tumor cell lines 
with RB gene mutations (data not shown). 
The above results demonstrate that selective downregula- 
tion of cyclin D1 is a phenomenon shared by cell lines trans- 
formed by DNA tumor virus oncoproteins known to form 
complexes with pRB and the tumor-derived cell lines har- 
boring mutations in the RB gene. This analogy suggested 
that he effect of the viral oncogene products upon cyclin D1 
expression could be indirect and possibly mediated through 
their association with pRB. To investigate his possibility, we 
tested the relative influence on cyclin D1 protein abundance 
of ectopically expressed wild type 12S EtA and an EtA mu- 
tant with a small deletion within the conserved region 2 do- 
main (E1A-ACP,2) which is highly homologous to corre- 
sponding RB-binding regions in SV-40 T antigen and 
papilloma E7 protein. The CR2 domain has been shown to 
mediate the high-affinity binding of EtA to the pRB's pocket 
region and the deletion mutant used in the present study 
failed to form complexes with pRB (Dyson and Harlow, 
1992; Fattaey et al., 1993). The SKLMS-1 sarcoma nd 
PMC42 breast cancer cell lines expressing wild type RB, 
standard levels of cyclin D1 and mutant p53 (to avoid apopto- 
sis upon EtA expression) were electroporated with either the 
EtA, E1A-~CR2, or a control pCMV-neo expression plas- 
raids, the cell populations resistant to O418 were selected 
over a period of 2-3 wk and the pooled clones lysed and ex- 
amined for EtA expression and cyclin D1 protein abundance. 
As seen in Fig. 6 A, introduction of both wild type E1A and 
EIA-ACR2 plasmids resulted in high-level expression of the 
respective proteins while no EtA protein could be detected 
in the control cell population electroporated with the pCMV- 
neo construct. The parallel immunoblotting analysis with 
DCS-6 antibody revealed a considerably lower level of cyclin 
D1 protein in the wild type EtA-expressing SKLMS-1 cells 
as compared with the cell population treated with the control 
plasmid (Fig. 6 A, bottom). In addition, cyclin D1 level in 
the cells expressing EtA-ACR2 mutant protein was not sig- 
nificantiy reduced when compared with the pCMV-neo con- 
trol (Fig. 6 A), implying that an intact CR2 region is essential 
for El~s ability to dcr~vnregulate cyclin D1 in SKLMS-1 
cells. Virtually identical data were obtained using the 
PMC42 breast cancer cell line as a recipient of the same x- 
pression plasmids (results not shown), indicating that he ob- 
served dependency of cyclin D1 downregulation on intact 
CR2 domain represents a common and reproducible phe- 
nomenon. We therefore conclude that the ability of E1A to 
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Figure 6. Gene transfer experiments indicating a positive role of 
pRB in regulation of cyclin D1 expression. (,4) Dowmegulation of 
cyclin D1 requires intact CR2 domain of adenovirus 5 EtA. The 
SKLMS-1 ceils were electroporated with expression vectors encod- 
ing the wild-type 12S EtA (lane 1) or EtA-CR2 mutant missing the 
L-X-C-X-E motif required for binding to pRB (lane 2). The immu- 
noblot demonstrates cyclin D1 levels in lysates of pooled clones 
preselected for 2 wk in G418-containing medium; lane 3 shows the 
data obtained with e control pCMV-neo vector. (B) Reintroduc- 
tion of wild-type RB cDNA into BT549 cells induces cyclin D1. 
BT549 cells were transiently electroporated with control pCMV 
plasmid (lane 1) or human RB cDNA in the same vector (lane 2). 
48-h later, the cells were lysed and assayed for RB and cyclin D1 
proteins by immunoblotting. Stable clones of BT549 cells express- 
ing pRB were also generated (e.g., lane 4) and found to accumulate 
higher levels ofcyclin D1 as compared to the G-418-resistant con- 
trol BT549 ceils lacking pRB (lane 3). The reference levels of both 
pRB and cyclin DI protein are shown in lane 5 (equal loading of 
CV-1 cell lysate). 
dowuregulate cyclin D1 expression is mediated through its 
complex formation with, and presumably functional inacti- 
vation of, the wild-type retinoblastoma protein. Further- 
more, since both SV-40 T antigen and papilloma virus E7 on- 
coproteins contain pRB-binding regions highly homologous 
to El~s CR2 sequence, a similar RB-mediated mechanism 
is likely to be responsible for cyclin D1 regulation by the lat- 
ter viral oncogene products as well. 
Taken together, the above data suggested that pRB could 
play a positive role in ~gulation of cyclin D1 expression. To 
address directly a requirement of functional pRB for the in- 
duction of cyclin D1, the wild type RB cDNA under the con- 
trol of the CMV promoter was electroporated into two RB- 
deficient umor ,.ell lines of different histogenesis (BT549 
breast carcinoma nd C33A cervical carcinoma lines) and 
the effect of transient as well as stable expression of pRB on 
the level of cyclin D1 was investigated by immunoblotting 
(after cotransfection of pSV-neo and pCMV-RB and selec- 
tion of G418-resistant, RB-expressing clones). Fig. 6 B, lane 
2 demonstrates that the expression of endogeneous cyclin D1 
is induced "m the pooled population of 131"549 cells which 
transiently express wild-type RB, and similarly, cyclin D1 
protein accumulates to significantly higher level in the stable 
clones which proliferate and express moderate l vels of the 
ectopically driven wild-type pRB (see Fig. 6 B, lane 4, for 
example). No effect on cyclin D1 expression is seen in BT549 
cells treated with the control plasmids (Fig. 6 B, lanes I and 
3). In addition, no detectable alterations of either cyclin A 
or cyclin E levels were seen upon expression of CMV-driven 
pRB, thus showing the specificity of the pRB-mediated stim- 
ulation for cyclin D1 (not shown). Virtually identical results 
in terms of specific yclin D1 stimulation were obtained also 
with, the C33A RB-deficient cell line using the same ex- 
perimental protocol. 
We conclude from this part of our Studies that: (a) cyclin 
D1 protein is expressed at normal levels in a wide spectnun 
of human tumor cell lines with normal RB gene and func- 
tional RB protein, irrespective of whether or not the p53 
gene is mutant in these cells; (b) cyclin D1 but not cycLin A 
expression is dramatically reduced in the cell lines carrying 
mutations in the retiuoblastoma gene; (c) cyclin D1 down- 
regulation by DNA virus oncoproteins requires intact RB- 
binding sequences; and (d) ectopic pRB induces cyclin D1 
but not cyclins A and E in RB-deficient ceils. Therefore, pRB 
appears to be involved in regulation of cyclin D1 expression 
in a positive manner. 
Cells with Mutant RB Lack the Cyclin D1 
Checkpoint in G1 but the Checkpoint Is Restored 
Upon Reintroduction of RB 
The above results showed that cyclin D1 functiqn becomes 
dispensable in cells expressing the RB-binding DNA virus 
oncoproteins, and that cyclin D1 is downregulated in cells 
lacking functional RB. These observations raise two impor- 
tant questions which must be answered to further elucidate 
the functional interplay between pRB and cyclin D1. Thus, 
we asked whether cyclin D1 protein is required or dispens- 
able for regulation of G1 phase progression i  cell lines car- 
rying mutant RB, and whether the level of cyclin D1 protein 
is of any functional significance for cell cycle regulation in 
such cells. To address these i sues through cyclin D1 knock- 
out experiments, we first selected three representative model 
cell lines which carry naturally occurring RB gene muta- 
tions (C33A, Saos-2, and BT549) (Table ID, and established 
a series of stable clones ectopically expressing elevated lev- 
els of cyclin D1 protein from one of these cell lines (BT549, 
see Fig. 7 A). The latter clones were prepared by cotransfect- 
ing the pCMV-D1 and pSV-neo plasmids at 10:1 ratio into 
BT549 breast cancer cell line, followed by G418 selection 
and immunoblotting analysis of cyclin D1 expression in ex- 
ponentially growing clonal cell populations. In the majority 
of clones, the cyclin D1 protein abundance was significantly 
increased as compared to the parental BT549 cells and varied 
from clone to clone (see Fig. 7 A for examples). The ectopi- 
cally expressed cyclic. D1 protein comigrated with the en- 
dogeneous protein ~d could be detected by antibodies to 
four different ep, itopes (not shown), thus indicating that it 
represents a genuine cycliwD1. Two clones with high expres- 
sion of the cyclin D1 protein approaching the levels seen in 
cultured diploid cells and in cancer cell lines with wild-type 
RB, were chosen for subsequent analysis, 
In keeping with our previous results, electroporation 
and/or microinjection of either the mouse monoclonal (clone 
DCS-6) or rabbit polyclonal antibodies to cyclin D1, but not 
of normal mouse or rabbit immunoglobulins, resulted in a 
severe inhibition of S-phase entry in human MCF-7 breast 
cancer cells (Fig. 7 B) which possess normal RB and p53 
CLee et al., 1988a; TAng et al., 1988; Casey etal., 1991; Bar- 
tek et al., 1992), single-copy cyclin D1 gene (Laramie et al., 
1991) and express an easily detectable cyclin D1 protein level 
(see Figs. 3 and 5). Essentially the same degree of the 
S-phase delay was obtained with the SK-LMS-1 cells (Fig. 
7 B) expressing functional RB protein (Stratton et al,, 1990; 
Bartek et al., 1992) and similar cyclin D1 level but carrying 
a mutation in the p53 gene (Stratton et al., 1990) and ac- 
cumulating the aberrant p53 protein (Bartek et al., 1993b). 
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Figure 7. Effect of anti-cyclin DI antibody knockouts upon onset 
of DNA synthesis incell lines with wild-type versus mutant RB. 
(,4) Immunoblotting analysis of cyclin DI abundance in xponen- 
tially growing RB-deficient parental BT549 cells (lane 1) and sev- 
eral clones derived from BT549 ceils by ccelectroporation of 
pCMV-Dl'and pSV-neo plasmids (lanes 2-8). Lane 9 shows the ref- 
erence level of cyclin D1 in CV-1 ceils expressing wild-type pRB.
Stable BT-549-derived clones (designated BT/DI+ series) express- 
ing the cyclin D1protein abundance approaching the standard levels 
seen in RB+ cell types were selected for the antibody-mediated 
knockout analysis. (B) Introduction of anti-cyclin D1 antibodies 
into synchronized c ll populations or inhibits S-phase entry of 
ceils with normal RB: MCF-7 (/), SKLMS-1 (2), and a BT549 clone 
stably reconstituted with wild-type RB (8),while no effect is ob- 
served in,cell lines with RB defects: BT-549 (3), Saos-2 (4), C33-A 
(5), and the two Cl nes of BT549 cells with ectopicaily expressed 
elevated levels of cyclin DI: clone BT/DI+ K-C2 (6) and B'r/DI+ 
K-A5 (7)..The data are expressed as graphs summarizing the per- 
centage of S-phase inhibition by DCS-6 and the extent of an x-
perimental error is indicated by standard deviation bars. 
Several other cell types with normal RB, which we xamined 
previously, showed very similar response to the cyclin D1 
knockout (Baldin et al., 1993; Lukas et all., 1994; Fig. 4). 
In contrast.to cell lines with wild-type RB, electroporation 
and/or microinjection fanti-cyelin D1 antibodies had no b- 
vious effect on G1 progression and S-phase ntry in any of 
the three tumor cell lines with mutations i  the RB gene (Fig. 
7 B). Since each of them shows a different degree of RB aber- 
ration, ranging from a homozygous loss in BT-549 (T~,ng et 
al., 1988), through a severe COOH-terminal deletion in 
Saos-2 cells (Shew et al., 1990), up to a subtle in-frame dele- 
tion of just four amino acid residues of exon 20 in C33-A 
cells (Scheffner et al., 1991), the lack of requirement for cy- 
clin D1 function appears to be a common feature of the can- 
cer cell lines with mutated RB gene. Furthermore, we ar- 
gued that the restoration ofthe normal cyclin D1 protein level 
in RB-deticient ceils could restore the cyclin D1 checkpoint, 
provided this cyclin D1 function is either independent of pRB 
or operates downstream ofpRB along the same pathway. The 
experiments aimed at elucidating this is ue revealed that he 
BT549-derived clones stably expressing cyclin D1 levels 
similar to those found in RB-positive cells remain refractory 
to cyclin D1 knockout (see Fig. 7 B, bars 6 and 7) indicating 
that he loss of cyclin D1 cell cycle regulatory function in RB- 
minus cells is not simply a consequence of low expression 
of this (31 cyclin. Additional immunoblotting analysis of 
these clones revealed the presence of apparently normal 
levels of cdk4, as well as p107 proteins, thus excluding 
the possibility hat the loss of cyclin D1 function is attribut- 
able to the lack of these partner proteins rather than pRB 
(data not shown). 
The lack of the cyclin D1 checkpoint in the cyclin DI- 
reconstituted BT549 clones was consistent with our view of 
pRB as a major target of cyclin D1 function in (31. On the 
other hand, the above data could also be explained if B'r549 
cells lost this checkpoint control through another, urdden- 
tiffed mutation, independent of RB and cyclin D1 level. To 
exclude the latter possibility, we performed a crucial control 
experiment by addressing the question whether the cyclin D1 
checkpoint would be restored upon reintroduction f wild- 
type RB into RB-deficient cells. Antibody-mediated cyclin 
D1 neutralization experiments were performed in two inde- 
pendent clones of the BT549 cells stably expressing ectopi- 
cally driven wild-type RB (see e.g., Fig. 6 B, lane 4 for RB 
and cyclin D1 protein levels in one of these clones), and in 
each case, a significant inhibition of S-phase ntry was de- 
tected (see Fig. 7 B, lane 8 for example). A similar degree 
of S-phase inhibition in the RB-reconstituted clones was ob- 
tained using either electroporation or microinjection of the 
antibodies, while control BI549 clones resistant to G418 but 
lacking RB remained refractory to the antibody-mediated 
cyclin D1 knockout (not shown). 
In summary, the results of the antibody knockout experi- 
ments are consistent with the notion that cyclin D1 protein's 
function is essential for cell cycle progression i cells with 
normal RB, regardless of whether wild-type or mutant p53 
protein is expressed in such cells. More importantly, our 
data strongly indicate that loss of the functional RB protein 
is accompanied by loss of the cell's requirement for the cell 
cycle regulatory function of cyclin D1, and that he cyclin D1 
checkpoint in (31 remains dispensable in the RB-deficient 
cells even upon restoration ofnormal cyclin D1 protein level. 
Upon RB reintroduction, however, the cyclin D1 checkpoint 
is restored, strongly supporting the notion that pRB func- 
tions downstream ofcyclin D1 along the G1 phase regulatory 
pathway. 
Discussion 
The control of proliferation i mammalian cells depends on 
mitogenic signals and other factors and is primarily con- 
cerned with a decision whether to withdraw from the cell cy- 
cle into quiescence (GO state) or to remain in the cell cycle 
and divide. This decision to commit to another round of cell 
division occurs during the GI phase and represents one of 
the key cell cycle checkpoints, often called the restriction 
point (Pardee, 1989). Aberrations in these decision-making 
processes can result in pathological proliferation which 
represents one of the hallmarks of cellular transformation. 
The transforming DNA viruses uch as SV-40, adenovirus, 
and the human papillomaviruses volved molecular mecha- 
nisms which allow them to verride both the G0>G1 and the 
restriction point controls of the host cell. These cell growth- 
regulating activities are carried out mainly by the viral early 
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genes including SV40 large T antigen, adeno type 5 EtA, and 
HPV16 and HPV18 E7 oncogenes (Dyson and Harlow, 1992; 
Fanning, 1992; Munger et al., 1992). These DNA virus- 
transforming gene products alter the transcription pattern of 
the cell, most likely through protein-protein targetting of the 
pRB-E2F and other egulatory complexes (Nevins, 1992). 
Despite the recent significant advances in our understanding 
of cell cycle regulation (Norbury and Nurse, 1992; Sherr, 
1993) and cellular transformation (Nevins, 1992; Motokura 
and Arnold, 1993), a great deal remains to be learned about 
these fundamental biological processes and the DNA virus 
oncogenes promise to provide invaluable tools in this field 
of research. 
The present study was designed to shed some light on the 
functional relationship between the product of the retino- 
blastoma gene (reviewed by Cobrinik et al., 1992; Goodrich 
and Lee, 1993), the RB-binding DNA virus oncoproteins, 
and one of the G1 cycllns, cyclin D1 CLew et al., 1991; Mat- 
sushime t al., 1991; Motokura et al., 1991; Xiong et al., 
1991). Here we report hat: (a) the SV-40 large T antigen, 
adenovirus E1A, and papillomavirus E7/E6 oncogenes 
downregulate expression ofcyclin D1 in a fashion apparently 
dependent on intact RB-interacting sequences; this down- 
regulation is not shared by other cyclins and appears to be 
exerted primarily at the mRNA level; (b) the retinoblastoma 
protein is involved in regulation of cyclin I)1 expression i  
a positive manner as suggested by very low abundance of this 
G1 cyclin in cancer cell lines containing mutated RB gene 
and by gene transfer experiments in which ectopically ex- 
pressed wild-type RB leads to specific induction of cyclin 
D1; and (c) the cyclin D1 protein, normally required for (31 
progression, is dispensable for passage through the cell cycle 
in cell lines whose pRB is inactivated through complex for- 
mation with T antigen, E1A, or E7 oncoproteins a well as 
in cells which have suffered loss-of-function mutations of the 
RB gene. This (31 phase checkpoint is not regained upon ex- 
perimental restoration of the normal cyclin D1 expression 
level, suggesting that pRB may serve as a major downstream 
target of cyclin D1 whose cell cycle regulatory function be- 
comes dispensable incells lacking functional RB. The latter 
view of the cyclin D1/pRB interplay is strongly supported by 
our present finding that he cyclin D1 checkpoint is restored 
upon reintroduction f wild-type RB into RB-deficient cell 
lines. 
In an attempt to integrate our new findings with the avail- 
able data in the field, we now propose amodel for a potential 
mechanism of concerted action ofpRB and cyclin D1 in regu- 
lation of (31 phase of the mammalian cell division cycle. 
Most recently, two hypotheses have been put forward by 
other investigators, in an attempt to explain the functional 
relationship between pRB and D-type cyclins. Thus, Dowdy, 
Weinberg, and colleagues have proposed that cyclin D1 pro- 
tein is downstream ofRB along the G1 regulatory pathway 
and is an object of negative regulation by pRB, mediated via 
physical protein-protein sequestration (Dowdy et al., 1993). 
An alternative xplanation has been offered by Ewen et al. 
(1993) who suggested that he pRB-cyclin D complex forma- 
tion can transiently target a pRB-phosphorylating cyclin- 
dependent kinase, preferentially cdk4, to the pRB substrate in
G1 phase, thereby inactivating its growth-suppressive func- 
tion. The salient and novel features of our present model in- 
clude the concept that pRB both regulates cyclin D1 and, in 
turn is an object of regulation by cyclin D1, thus creating a
kind of an autoregulatory loop operating in 131. Inherent in 
our model is also a key proposition that pRB serves as a ma- 
jor target of the cell cycle regulatory function of cyclin D1 
(Fig. 8). We propose that in normal cells, as in tumor cells 
with preserved normal RB gene and functional RB protein, 
cyclin D1 protein (Fig. 8, pD1) abundance oscillates in a cell 
cycle-dependent manner, starting from low level in early G1, 
raising up to its peak level in mid/late G1, followed by a 
gradual decay in late (;1 and through G1/S and early S-phase, 
eventually reaching its lowest level in advanced S-phase (Fig. 
8 A). Consistent with our proposal, such a cell cycle-related 
fluctuation profile of cyclin D1 levels has been reported for 
several normal and tumor cell types containing wild-type RB 
(Motokura et al., 1992; Baldin et al., 1993; Musgrove t al., 
1993; Bartkova et al., 1994; Lukas et al., 1994) while it was 
less obvious in cells transformed byDNA tumor virus on- 
cogenes (Matsushime t al., 1991; Motokura et al., 1991). 
The transcriptional ctivation from the cyclin D1 promoter 
would be driven, directly or indirectly, by the underphos- 
phorylated, active form of pRB, present in early and mid (31 
(Buchkovich et al., i989; reviewed in Cobrinik et al., 1992; 
Goodrich and Lee, 1'993). The positive role of pRB in regu- 
lation of cyclin D1 expression is supported by this study as 
well as by Our results (Miiller et al., 1994) demonstratlng i - 
duction of cyclin D1 mRNA by transfection of the RB gene 
into RB-deficient cells and by dose-dependent stimulation of 
a cyclin D1 promoter-driven reporter gene expression by 
cotran.~fected wild-type but not mutant RB gene. This trans- 
activating form of pRB is likely to include aprotein-protein 
complex of hypophosphorylated pRB with either a positive 
or inhibitory transcription factor. While the former complex 
could either stimulate he transcription fthe cyclin D1 gene 
promoter directly or through activation of another interme- 
diate, the latter complex could serve to sequester a relevant 
transcriptional inhibitor, thereby allowing the cyclin D1 tran- 
scription to proceed. Upon inactivation ofpRB through phos- 
phorylation in late (31 (reviewed by Cobrinik et al., 1992; 
Goodrich and Lee, 1993), the specific transcription fcyclin 
D1 would be shut off or decreased, correlating with the above 
oscillation of cyclin D1 protein and reflecting the reported 
short half life of both cyclin D1 mRNA and protein (Matsu- 
shime et al., 1991; Sewing et al., 1993). During early G1, 
the pocket region of hypophosphorylated pRBspecies inter- 
act with numerous cellular Rb-binding proteins' (CRBP) 
(Fig. 8), which include the E2F transcription factor, other 
reported pRB-binding cellular partners (see Huang et al., 
1991; Kaelin et al., 1991; Herin et al., 1992), and potentially 
the factor involved in the transcriptional regulation of cyclin 
D1 (see above). With the increasing cyclin D1 protein uclear 
abundance in advanced G1 phase, more and more pRB pocket 
space would be occupied by cyclin D1, possibly competing 
out and releasing other CRBPs and, at the same time, tran- 
siently targetting a pRB-phosphorylating kinase (most likely 
cdk4) to this substrate. Consistent with this part of the model 
is the accumulating evidence for direct physical interaction 
of D-type cyclins with unphosphorylated an /or underphos- 
phorylated pRB via their NH2-terminal L-X-C-X-E motifs 
analogous to those present in homology regions II of the 
DNA virus oncoproteins (Dowdy et al., 1993; Ewen et al., 
1993; Kate et al., 1993), the ability ofD-type cyclins to re- 
lieve the pRB's cell growth-constraining function in RB-minus 
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Figure 8. Schematic represen- 
tation of the proposed au- 
toregulatory loop interaction 
between pRB and cyclin DI, 
involved in regulation of 
G1 phase progression. (,4) 
Represents a situation appli- 
cable for normal cycling cells 
and tumor cells which possess 
wild-type RB and single-copy 
cyclin D1 gene. (B) Shows 
aberrations of the RB/cydin 
D1 regulatory mechanism 
caused by DNA tumor virus 
oncoproteins, RB gene muta- 
tions, and cyclin D1 overex- 
pression resulting from either 
gene amplification or trans- 
location. For detailed expla- 
nation of this model, see text 
in the Discussion section. 
Symbols used in this figure: 
pRB, retinoblastoma protein; 
pD1, cyclin D1 protein, CRBP, 
cellular Rb-binding protein; 
cdk, cyclin-dependent kina~e; 
MpRB, mutant RB protein; T, 
E1A, E7, respective DNA virus 
oncoproteins; P, phosphate 
group; TF-X, postulated tran- 
scription factor involved ([x~- 
tentially complexed to pRB) 
in regulation of the cydin D1 
gene promoter. 
ceils (Hinds et al~, 1991; Dowdy et al., 1993; Ewen et al., 
1993), and the capacity of the cyclin D-associated kinase(s) 
to selectively ph0sphorylate the RB protein (Kato et al., 
1993; Matsusbime t al., 1992). Both the competition for 
available pRB pockets and the pRB phosphorylation with the 
concomitant conformational change of pRB would result in 
free CRBPs, released from their captivity and ready to trig- 
ger S-phase entry. The major task of cy~lin D1 cell cycle 
regulatory mission would thus be compieti~d by late G1 and 
its abundance would drop due to the lack of transcriptional 
Stin~ulation by underph0sphorylatod pRB, thereby closing 
one circle of the proposed autoregulatory loop (Fig. 8 A). 
The decision whether to enter ano&ef loop cycle or with- 
drawal into quiescence is likely to be ir/fluenced by available 
mitogens and other factors ~nvol#ed in the regulatory recep- 
tor-mediated network controlling cell proliferation, which 
eventually passes the message on the RB/cydin D1 loop in G1. 
This normal, physiological mechanism can potentially be- 
come disregulated in various ways but at least three biologi- 
cally relevant scenarios can easily be documented using our 
model as a mechanistic basis. First, the transforming onco- 
genes of several DNA tumor viruses, including SV-40 T anti- 
gen, adenovirus E1A, and papillomavirus E7 oncoproteins 
are known to subvert he cell cycle regulation of the target 
cells, at least in part, by complexing to hypophosphorylated 
pRB (Ludlow et al., 1989; Imai et al., 1991; Dyson and 
Harlow, 1992). We report here that cyclin D1 protein level 
is very low in cells transformed by the above viral oncogenes 
and, in addition, that the remaining cyclin D1 protein is no 
longer required for (31 progression i these cells, and down- 
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regulation of cyclin D by adenovirus E1A has also been ob- 
served by Buchou et al., 1993. According to our model (Fig. 
8 B), tight complex formation with the respective viral on- 
coproteins would occupy the available pRB pockets in G1, 
thereby preventing pRB's normal transactivating role in stim- 
ulation of cyclin D1 transcription. At the same time, since 
pRB's growth-suppressive function is already neutralized by 
the viral oncoproteins in such cells, cyclin D1 protein loses 
its major target and is dispensable for the aberrant cell cy- 
cling under these conditions. Second, a situation analogous 
to that just described for the virally transformed cells can be 
envisaged for cancer ceils which have suffered loss of func- 
tion mutations in the RB gene (reviewed by Cobrinik et al., 
1992; Goodrich and Lee, 1993) or cells with experimentally 
repressed RB expression (Strauss et al., 1992). The muti- 
lated pRB pockets would be unable to complex with either 
CRBPs or cyclin D1, accounting for unconstrained progres- 
sion into S-phase due to free CRBPs, lack of phosphoryla- 
tion typical for the mutant RB gene products, low levels of 
cyclin D1, and loss of requirement for cyclin D1 function, 
consistent with our experimental data reported here and with 
the proposed model (Fig. 8 B). Third, cyclin D1 gene is re- 
arranged and/or amplified in several types of human malig- 
nancies, resulting in overexpression and consistent with the 
current opinion classifying this cell cycle regulator as a can- 
didate proto-oncogene ( .g.I.ammie t al., 1991; Motokura 
et al., 1991; reviewed by Motokura and Arnold, 1993). 
When considering this situation in the framework of our 
model, abnormally high level of cyclin D1 in G1 phase of the 
cell cycle would lead to a more efficient occupation of the 
pRB pockets, faster inactivation of pRB through phosphory- 
lation and premature S phase entry due to release of free 
CRBPs (Fig. 8 B). In fact, this prediction of our model is 
also consistent with a recent report that moderate overex- 
pression of D-type cyclins leads to shortening of G1 phase 
and correspondingly faster cell division cycles in mouse 
fibroblasts (Quelle et al., 1993). 
As any other model, the proposed mechanism summarized 
in Fig. 8 should be regarded as a working hypothesis aimed 
to stimulate further research to elucidate the as yet uncertain 
structural and functional aspects of the RB-cyclin D1 inter- 
action. The results summarized in the present report, to- 
gether with the known involvement of both RB and cyclin D1 
in molecular oncogenesis (reviewed by Cobrinik et al., 1992; 
Goodrich and Lee, 1993; Motokura and Arnold, 1993) sug- 
gest a central role of this regulatory interplay between the 
products of a cellular tumor suppressor gene and a cell cycle 
regulatory proto-oncogene, in control of the G1 phase pro- 
gression at the point highly reminiscent of the restriction 
point proposed by Pardee (1989). 
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